Literature DB >> 17525041

Treatment guidelines in ovarian cancer.

A Poveda Velasco1, A Casado Herráez, A Cervantes Ruipérez, D Gallardo Rincón, E García García, A González Martín, G López García, C Mendiola Fernández, B Ojeda González.   

Abstract

National and international specialists have met with the aim of writing down the guidelines for the treatment of epithelial ovarian cancer (in the Spanish Castilian language). These guidelines are based on the International Consensus that was published in English in the Annals of Oncology in 2005. This condition is the leading cause of death from gynaecological cancer in western countries. Its low rate of survival, barely 30% at 5 years, is above all due to late diagnosis and inappropriate surgery, so emphasis is put on these aspects. After describing the methodology for early detection and a scheme of surgical diagnostic procedures in view of the staging of an ovarian mass, the following therapeutic strategies will be recommended: cytoreductive surgery together with platinum chemotherapy under normal conditions, and also in the case of relapse. Likewise, very recent models of treatment focused on molecular targets are presented, and a broad section on methodology of clinical assays. As for this, co-operation among groups is crucial in order to make the conclusions of these studies valid for the development of new therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17525041     DOI: 10.1007/s12094-007-0058-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  51 in total

1.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.

Authors:  S M Eisenkop; R L Friedman; N M Spirtos
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

2.  Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

Authors:  I Vergote; G J Rustin; E A Eisenhauer; G B Kristensen; E Pujade-Lauraine; M K Parmar; M Friedlander; A Jakobsen; J B Vermorken
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

3.  The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

Authors:  J R van Nagell; P D DePriest; M B Reedy; H H Gallion; F R Ueland; E J Pavlik; R J Kryscio
Journal:  Gynecol Oncol       Date:  2000-06       Impact factor: 5.482

Review 4.  Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?

Authors:  E A Eisenhauer; M Gore; J P Neijt
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

5.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

6.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

7.  Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument.

Authors:  C Tropé; J Kaern; T Hogberg; V Abeler; B Hagen; G Kristensen; M Onsrud; E Pettersen; P Rosenberg; R Sandvei; K Sundfor; I Vergote
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

8.  The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis.

Authors:  G Zanetta; S Rota; S Chiari; C Bonazzi; G Bratina; V Torri; C Mangioni
Journal:  Ann Oncol       Date:  1998-10       Impact factor: 32.976

9.  International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

Authors:  J Baptist Trimbos; Mahesh Parmar; Ignace Vergote; David Guthrie; Giorgio Bolis; Nicoletta Colombo; Jan B Vermorken; Valter Torri; Constantino Mangioni; Sergio Pecorelli; Andrea Lissoni; Ann Marie Swart
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

10.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

Authors:  Paul A Vasey; Gordon C Jayson; Alan Gordon; Hani Gabra; Rob Coleman; Ronnie Atkinson; David Parkin; James Paul; Andrea Hay; Stan B Kaye
Journal:  J Natl Cancer Inst       Date:  2004-11-17       Impact factor: 13.506

View more
  8 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway.

Authors:  Hong Zhu; Jun Gao; Lei Wang; Ke-Jian Qian; Li-Ping Cai
Journal:  Exp Ther Med       Date:  2018-01-04       Impact factor: 2.447

3.  Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in ovarian cancers.

Authors:  An-Cong Wang; Feng-Xia Wu; Yong-Sheng Gao; Xiu-Gui Sheng
Journal:  Oncol Lett       Date:  2014-05-07       Impact factor: 2.967

4.  Expression of the tumor suppressor gene p16, and lymph node metastasis in patients with ovarian cancer.

Authors:  Hongyan Wang; Jingfang Zheng; Qiang Li; Min Zhou; Dongmei Ai; Hui Zhang
Journal:  Oncol Lett       Date:  2017-08-08       Impact factor: 2.967

Review 5.  Role of the microenvironment in ovarian cancer stem cell maintenance.

Authors:  Jennifer Pasquier; Arash Rafii
Journal:  Biomed Res Int       Date:  2012-12-24       Impact factor: 3.411

6.  GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012.

Authors:  A González Martín; A Redondo; M Jurado; A De Juan; I Romero; I Bover; J M Del Campo; A Cervantes; Y García; J A López-Guerrero; C Mendiola; J Palacios; M J Rubio; A Poveda Velasco
Journal:  Clin Transl Oncol       Date:  2013-03-07       Impact factor: 3.405

7.  The effect of sortilin silencing on ovarian carcinoma cells.

Authors:  Fatemeh Ghaemimanesh; Gholamreza Ahmadian; Saeed Talebi; Amir-Hassan Zarnani; Mehrdad Behmanesh; Shayda Hemmati; Reza Hadavi; Mahmood Jeddi-Tehrani; Maryam Farzi; Mohammad Mehdi Akhondi; Hodjattallah Rabbani
Journal:  Avicenna J Med Biotechnol       Date:  2014-07

Review 8.  Role of mesenchymal cells in the natural history of ovarian cancer: a review.

Authors:  Cyril Touboul; Fabien Vidal; Jennifer Pasquier; Raphael Lis; Arash Rafii
Journal:  J Transl Med       Date:  2014-10-11       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.